AI-Driven Preclinical Advances in Nuclear Medicine Radiopharmaceutical Therapy for Prostate Cancer
- 24 April 2025
- book chapter
- Published by IGI Global Scientific Publishing
- p. 203-230
Abstract
Radiopharmaceutical therapy represents a growing treatment modality in prostate cancer, and this chapter will focus on how Artificial Intelligence (AI) can be applied to preclinical development of this treatment paradigm. The study, presents a Multi-Modal Attention Enhanced Neural Network (MAENN) to integrate disparate data types—imaging, molecular and pharmacokinetics—to improve predictions of therapy efficacy, determination of optimal dose and the identification of specific biomarkers. Compared to a number of conventional models such as SVMs and CNNs, MAENN maintains the highest accuracy in prediction, sensitivity and data integration capabilities. Although issues like data quality and computational complexity remain, the chapter also describes the scalability, potential for real-time applications, and future applications of MAENN in other cancer therapies, contributing towards personalizing treatment strategies in order to pave the way for precision oncology.Keywords
This publication has 13 references indexed in Scilit:
- Integrated normal discriminant analysis in mapreduce for diabetic chronic disease prediction using bivariant deep neural networksInternational Journal of Information Technology, 2024
- Brain Tumor Detection for Efficient Adaptation and Superior Diagnostic Precision by Utilizing MBConv-Finetuned-B0 and Advanced Deep LearningInternational Journal of Intelligent Engineering and Systems, 2024
- AI-Enhanced Comprehensive Liver Tumor Prediction using Convolutional Autoencoder and Genomic SignaturesInternational Journal of Advanced Computer Science and Applications, 2024
- On the Use of Artificial Intelligence for Dosimetry of Radiopharmaceutical TherapiesNuklearmedizin-Nuclear Medicine, 2023
- Marshalling the Potential of Auger Electron Radiopharmaceutical TherapyJournal of Nuclear Medicine, 2023
- Preclinical Development in Radiopharmaceutical Therapy for Prostate CancerSeminars in Nuclear Medicine, 2023
- The Impact of Radiopharmaceutical Therapy on Renal FunctionSeminars in Nuclear Medicine, 2022
- Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary ApproachCurrent Radiopharmaceuticals, 2022
- Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer CareJNCI Cancer Spectrum, 2021
- Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trialRadiotherapy and Oncology, 2021